Physician profile
Abel J Paredes
NPI 1932168614
$1,408.53
in general payments reported to CMS, 2019-2025
23 companies · $240 in 2025
The $240 reported for 2025 was more than what 79% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $147 · 2021: $157 · 2022: $89.90 · 2023: $237 · 2024: $199 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $676.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $318.55 | 2019-2025 | |
| Cranial Technologies, INC | $177.75 | 2019-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $141.43 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Glaxosmithkline, LLC. | $106.11 | 2019-2023 | Bexsero |
| Alexion Pharmaceuticals, INC. | $98.60 | 2019 | |
| Sanofi-Aventis U.S. LLC | $83.53 | 2023-2025 | |
| Pfizer INC. | $63.96 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $49.05 | 2025 | Daybue |
| Genentech USA, INC. | $45.57 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.68 | 2020-2021 | |
| Phadia US INC. | $38.16 | 2019 | |
| Seqirus USA INC | $34.41 | 2022-2023 | Flucelvax Quadrivalent |
| Verrica Pharmaceuticals INC. | $28.84 | 2024 | Ycanth |
| Astrazeneca Pharmaceuticals LP | $24.58 | 2023 | Flumist Quadrivalent |
| Ironshore Pharmaceuticals INC. | $22.73 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $20.55 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $20.04 | 2021 | |
| Lnhc, INC | $19.02 | 2025 | Zelsuvmi |
| Collegium Pharmaceutical, INC. | $17.06 | 2025 | Jornay Pm |
| Medline Industries LP | $16.85 | 2019 | |
| Alk-Abello, INC | $15.75 | 2025 | Neffy |
| Azurity Pharmaceuticals, INC. | $13.92 | 2025 | Alvesco |
| Adlon Therapeutics L.P. | $13.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abel Paredes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.